• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

CytoRad dispute lowers Cytogen revenues

Article

Monoclonal antibody developer Cytogen reported a sharp drop in its 1994 revenues as a resultof its dispute last year with sister company CytoRad. Cytogen,of Princeton, NJ, had total revenues for 1994 (end-December) of$2.5 million, down from $10.4 million

Monoclonal antibody developer Cytogen reported a sharp drop in its 1994 revenues as a resultof its dispute last year with sister company CytoRad. Cytogen,of Princeton, NJ, had total revenues for 1994 (end-December) of$2.5 million, down from $10.4 million in 1993. Cytogen's net lossfor the year was $32.8 million, compared to a net loss of $29.2million a year ago.

The revenue shortfall was caused by the absence of contractrevenue from CytoRad, which had contributed $7.9 million to Cytogen'sbalance sheet in 1993. CytoRad, formed to fund R&D at Cytogen,cut off its contributions last year after a dispute over theirbusiness relationship (SCAN 6/29/94 and 4/20/94).

Cytogen is hoping to put the CytoRad affair behind it by acquiringthat company, and Cytogen reported that its stockholders approvedthe acquisition at a special meeting held on Feb. 23.

Outside of the CytoRad shortfall, Cytogen's 1994 numbers painteda picture of a company that is cutting operating expenses andexperiencing increased sales of its OncoScint CR/OV monoclonalantibody imaging agent. OncoScint product sales for the fourthquarter of 1994 were $480,000 compared to $259,000 in the sameperiod a year ago. Cytogen cut operating expenses 16% comparedto the year before. The company recorded a charge of $4.1 millionin the fourth quarter in connection with the CytoRad acquisitionas well as its reacquisition of OncoScint marketing rights fromKnoll Pharmaceutical.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.